Brief: Uni-Bio Science Group Says Application For Clinical Trial Of Recombinant Exendin-4 Injection Accepted By NMPA
15/07/2020 16:21
July 15 (Reuters) - Uni-Bio Science Group Ltd 0690.HK :
* APPLICATION FOR CLINICAL TRIAL OF RECOMBINANT EXENDIN-4
INJECTION ACCEPTED BY NMPA
Source text for Eikon: urn:newsml:reuters.com:*:nHKSBfGZ7
Further company coverage: 0690.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Uni-Bio Science
See all newsBrief: Uni-Bio Science Signs Agreement With WMU NERC And Wenzhou Ouhai District Government
Brief: Uni-Bio Science's Unit Expands Global Reach Of Bogutai Through Strategic Partnership
Brief: Uni-Bio Science Group Says Marketing Application Of Isavuconazonium- Sulfate Capsules Accepted NMPA
Brief: Uni-Bio Science Group Says Marketing Application Of Diquafosol Sodium Eye Drops Officially Approved By NMPA
Brief: Uni-Bio Science Declares Final Dividend Of Hk0.277 Cents Per Share